MiNK Therapeutics, Inc.
INKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.03 | -0.00 | -0.08 |
| FCF Yield | -4,033.63% | -5.33% | -3,914.12% | -6.57% |
| EV / EBITDA | 0.00 | -7.94 | -13.31 | -12.33 |
| Quality | ||||
| ROIC | 0.00% | 71.30% | 92.60% | 202.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.33 | 0.37 | 484.65 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -159,788.35% | 99.88% | -77,511.95% | 42.31% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.91 | -0.69 | -0.16 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -6,118.07 | -4,717.97 | -4,558.08 |